Back to User profile » Dr Alexandria Lee
Papers published by Dr Alexandria Lee:
Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report
Lee ATM, Park CJ, Arter ZL, Nagasaka M, Ou SHI
Lung Cancer: Targets and Therapy 2025, 16:199-203
Published Date: 25 December 2025
Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC
Lee AT, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:169-176
Published Date: 17 December 2024
LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC
Lee ATM, Ou SI
Lung Cancer: Targets and Therapy 2024, 15:75-80
Published Date: 23 May 2024
Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver
Lee ATM, Ou SI
Lung Cancer: Targets and Therapy 2024, 15:19-27
Published Date: 27 February 2024
ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia
Lee AT, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:71-78
Published Date: 7 July 2023
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting
Lee AT, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:57-62
Published Date: 22 June 2023
CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC
Lee ATM, Nagasaka M
Lung Cancer: Targets and Therapy 2023, 14:41-46
Published Date: 25 April 2023
CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code
Zhang SS, Lee A, Nagasaka M
Lung Cancer: Targets and Therapy 2023, 14:27-30
Published Date: 19 April 2023